Organon & Co. (OGN) Competitors $9.46 -0.18 (-1.87%) Closing price 03:59 PM EasternExtended Trading$9.47 +0.01 (+0.10%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Blueprint Medicines (NASDAQ:BPMC) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has higher valuation and earnings, BPMC or OGN? Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M16.43-$67.09M-$2.47-52.42Organon & Co.$6.40B0.38$864M$2.883.28 Do analysts recommend BPMC or OGN? Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.95%. Organon & Co. has a consensus target price of $18.00, suggesting a potential upside of 90.27%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Does the media favor BPMC or OGN? In the previous week, Organon & Co. had 50 more articles in the media than Blueprint Medicines. MarketBeat recorded 58 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.15 beat Organon & Co.'s score of 0.27 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 42 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Neutral Which has more risk & volatility, BPMC or OGN? Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Do institutionals and insiders hold more shares of BPMC or OGN? 77.4% of Organon & Co. shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is BPMC or OGN more profitable? Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% Organon & Co. 11.92%227.43%7.34% SummaryOrganon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Medical Services IndustryMedical SectorNYSE ExchangeMarket Cap$2.51B$6.98B$5.54B$20.85BDividend Yield0.83%2.88%3.75%3.65%P/E Ratio3.2826.7928.0127.55Price / Sales0.3836.65433.8159.20Price / Cash1.9628.0836.1622.29Price / Book5.179.018.124.66Net Income$864M$233.10M$3.25B$994.58M7 Day Performance-4.83%-0.15%0.97%-0.29%1 Month Performance-4.31%1.22%7.36%4.91%1 Year Performance-54.90%23.83%31.31%10.53% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.8555 of 5 stars$9.46-1.9%$18.00+90.3%-54.4%$2.51B$6.40B3.284,000Trending NewsBPMCBlueprint Medicines1.0758 of 5 stars$128.40+0.0%$128.06-0.3%+13.2%$8.29B$508.82M-51.98640News CoveragePositive NewsBBIOBridgeBio Pharma4.6238 of 5 stars$43.50-1.1%$58.85+35.3%+67.0%$8.26B$221.90M-12.32400Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.2988 of 5 stars$91.20-0.4%$107.36+17.7%+358.8%$7.76B$42.28M-45.6030ROIVRoivant Sciences2.6714 of 5 stars$10.74-2.3%$17.50+62.9%+3.6%$7.30B$29.05M-42.96860Positive NewsELANElanco Animal Health1.8068 of 5 stars$14.48-1.1%$15.33+5.9%+14.6%$7.19B$4.44B19.579,000Analyst UpgradeAnalyst RevisionRVMDRevolution Medicines4.5503 of 5 stars$36.67-3.2%$67.58+84.3%-15.9%$6.83B$11.58M-9.17250Analyst ForecastLEGNLegend Biotech3.5835 of 5 stars$35.87+0.6%$72.60+102.4%-23.4%$6.59B$728.30M-60.802,609News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.8994 of 5 stars$8.87-2.3%$10.30+16.1%+24.7%$6.10B$7.81B7.5823,822News CoverageTGTXTG Therapeutics3.4049 of 5 stars$35.98-2.0%$40.80+13.4%+77.5%$5.71B$329M149.92290NUVLNuvalent3.1882 of 5 stars$77.93-3.2%$119.60+53.5%+6.4%$5.60BN/A-17.7540Insider Trade Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives VRNA Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives LEGN Alternatives GRFS Alternatives TGTX Alternatives NUVL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.